StreetInsider.com News Articles

Jefferies: 'We continue to view KLRA as one of the most attractive late-staged SMID obesity play'

Wed, 07 Oct 2026 09:26:28 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $48.00 price target on Kailera Therapeutics (NASDAQ: KLRA).

The analyst comments "We hosted KLRA mgmt for a Boston NDR following completion of enrollment across the ribupatide Ph3 KaiNETIC program. Discussions focused on the remaining Ph3 execution into 2028 data, high-dose ribupatide optionality, oral ribupatide's planned Ph3 start in 1H27, KAI-7535's upcoming 2027 Ph2 readout, and KAI-4729 as a second potential high-efficacy asset. Mgmt emphasized breadth of portfolio, multiple shots on goal, and a catalyst-rich ~12-18 month ahead. Bottom line. We continue to view KLRA as one of the most attractive late-staged SMID

Kailera shares Phase 1 ribupatide injection site data at EASD

Thu, 01 Oct 2026 06:46:01 -0400

Kailera Therapeutics (Nasdaq: KLRA) presented Phase 1 clinical data for its ribupatide injection at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, according to a company statement.

The Phase 1 single-dose, crossover trial enrolled 51 adults with obesity or overweight and evaluated three subcutaneous injection sites — abdomen, upper arm, and thigh. Each participant received a single 2 mg dose of ribupatide per treatment period. The trial found that plasma drug exposure following injection to the upper arm or thigh was similar to that observed with abdominal injection. Most treatment-emergent adverse events were

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Thu, 01 Oct 2026 06:45:00 -0400

- New Phase 1 data highlight flexibility of injection site for ribupatide injection

- Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). In

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Thu, 01 Oct 2026 06:45:00 -0400

- New Phase 1 data highlight flexibility of injection site for ribupatide injection

- Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline

Kailera completes enrollment in Phase 3 obesity drug trial

Wed, 30 Sep 2026 07:00:39 -0400

Kailera Therapeutics (Nasdaq: KLRA) has completed enrollment in its KaiNETIC global Phase 3 clinical program, evaluating ribupatide injection (KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonist, for the treatment of obesity and overweight. Topline data from the three trials are now expected in mid-2028, according to a company statement.

The KaiNETIC program comprises three double-blind, randomized, placebo-controlled trials conducted at more than 200 investigative sites across eleven countries in North America, Europe, the United Kingdom, Oceania, and South America. Doses of up to 10 mg are administered by weekly subcutaneous injection over 76 weeks, with dose titration for up to 24

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Wed, 30 Sep 2026 07:00:00 -0400

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher

- Topline data now expected in mid-2028

WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531),

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Wed, 30 Sep 2026 07:00:00 -0400

- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher

- Topline data now expected in mid-2028

Kailera Therapeutics to Participate in September Investor Conferences

Wed, 16 Sep 2026 07:00:00 -0400

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences:

Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum
Wednesday, September 23, 2026, 9:40 a.m. ET
Fireside Chat with Jamie Coleman, Chief Commercial Officer

Stifel 2026 Virtual Cardiometabolic Forum
Wednesday, September 30, 2026, 11:30 a.m. ET
Fireside Chat with Ron Renaud, Chief Executive Officer, Doug Pagán, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer

The

Kailera Therapeutics to Participate in September Investor Conferences

Wed, 16 Sep 2026 07:00:00 -0400

Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum
Wednesday, September 23, 2026, 9:40 a.m. ET
Fireside Chat with Jamie Coleman, Chief Commercial Officer

Stifel 2026 Virtual Cardiometabolic Forum
Wednesday, September 30, 2026, 11:30 a.m. ET
Fireside Chat with Ron Renaud, Chief Executive Officer, Doug Pagán, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer

The

Form SCHEDULE 13G Kailera Therapeutics, Filed by: CANADA PENSION PLAN INVESTMENT BOARD

Fri, 14 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26929918.html

Form SCHEDULE 13G Kailera Therapeutics, Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26924879.html

Form 10-Q Kailera Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913436.html

Form 8-K Kailera Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260812/26913254.html

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Wed, 12 Aug 2026 16:05:00 -0400

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027
Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027
Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership
Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Wed, 12 Aug 2026 16:05:00 -0400

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027
Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027
Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership
Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028

Kailera Therapeutics names Nur Nicholson as chief technology officer

Tue, 11 Aug 2026 07:00:45 -0400

Kailera Therapeutics, Inc. (Nasdaq: KLRA) announced the appointment of Nur Nicholson as chief technology officer, effective Aug. 31, 2026.

Nicholson brings nearly three decades of experience in technical operations, manufacturing, quality, and supply chain across the pharmaceutical and biotechnology industries. She previously served as chief technical operations officer at Apellis Pharmaceuticals, where she led the company's transition from a clinical-stage organization to a commercial-scale enterprise.

Prior to Apellis, Nicholson held the role of head of global supply chain and vice president of North American business operations at Galderma, overseeing supply chain operations for a $10 billion dermatology and aesthetics organization active in

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

Tue, 11 Aug 2026 07:00:00 -0400

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026.

“We are excited to welcome Nur as an executive at such a pivotal moment for Kailera,” said Ron Renaud, President and Chief Executive Officer of Kailera. “As we advance ribupatide injection through global Phase 3 trials, look

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

Tue, 11 Aug 2026 07:00:00 -0400

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

Form SCHEDULE 13G Kailera Therapeutics, Filed by: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869500.html

Form 4 Kailera Therapeutics, For: Jul 06 Filed by: Tregoning Kathleen

Wed, 08 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260708/26747819.html

Form 3 Kailera Therapeutics, For: Jun 29 Filed by: Tregoning Kathleen

Wed, 08 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260708/26747738.html

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Mon, 29 Jun 2026 07:30:00 -0400

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.

“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Mon, 29 Jun 2026 07:30:00 -0400

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Mon, 29 Jun 2026 07:30:00 -0400

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Mon, 29 Jun 2026 07:30:00 -0400